Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SFDA Proposes New Review Channel For Innovative Drugs

This article was originally published in PharmAsia News

Executive Summary

Pressured by increasing calls from industry, China’s State FDA released a new proposal to expedite new drug reviews, focusing on drugs with high clinical value.

You may also be interested in...



China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference

SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7

As WHO Rings COVID Zero Alarm, Study Says China Vaccination 'Insufficient'

The WHO calls the "COVID Zero" containment policy that Beijing is doubling down on "unsustainable," while a new study has shed light on the potential cost of moving away from cutting transmissions to mitigating disease. 

US Delisting Risk Hits I-Mab Hard, Bilateral Agreement Needed?

It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel